000281503 001__ 281503
000281503 005__ 20251102002042.0
000281503 0247_ $$2doi$$a10.3389/fimmu.2025.1642250
000281503 0247_ $$2pmid$$apmid:40995367
000281503 0247_ $$2pmc$$apmc:PMC12454094
000281503 0247_ $$2altmetric$$aaltmetric:181532850
000281503 037__ $$aDZNE-2025-01124
000281503 041__ $$aEnglish
000281503 082__ $$a610
000281503 1001_ $$aVogelgesang, Antje$$b0
000281503 245__ $$aAnti-neuronal and anti-mitochondrial autoantibodies are associated with lower functional status and more severe respiratory symptoms in post COVID syndrome.
000281503 260__ $$aLausanne$$bFrontiers Media$$c2025
000281503 3367_ $$2DRIVER$$aarticle
000281503 3367_ $$2DataCite$$aOutput Types/Journal article
000281503 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761731128_30627
000281503 3367_ $$2BibTeX$$aARTICLE
000281503 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281503 3367_ $$00$$2EndNote$$aJournal Article
000281503 520__ $$aWe previously identified IgG autoantibodies targeting epitopes within brainstem proteins-disabled homolog 1 (DAB1), apoptosis-inducing factor 1 (AIFM1), and surfeit locus protein 1 (SURF1)-as markers of severe acute COVID-19. This study investigates whether the same autoantibodies contribute to the pathophysiology of Post COVID Syndrome (PCS).Using a multiplexed bead-based immunoassay, we measured IgG levels against 18 synthetic peptides derived from DAB1, AIFM1, and SURF1 in serum samples from 45 PCS patients and 30 post-COVID controls without long-term symptoms. We employed generalized linear mixed models (GLMM) and nonlinear principal component analysis (CATPCA) to explore associations between antibody levels and clinical variables, including functional status (PCFS), respiratory symptoms, fatigue, cognitive impairment (as assessed by the Montreal Cognitive Assessment, MoCA), and mood.Higher IgG levels against the three autoantigens significantly predicted PCS at 3 months postinfection (t=2.21, p=0.03), whereas antibodies against a control peptide (polio) showed no such association. CATPCA identified a principal component capturing respiratory symptoms and functional impairment (PCFS), which was also significantly predicted by autoantibody levels (t=2.04, p=0.04). MoCA scores did not correlate with autoantibody levels, and subjective cognitive complaints were paradoxically linked to lower antibody titers and fewer physical symptoms.The findings from the present explorative study, although largely correlative, appear to suggest a sustained autoimmune response targeting neuronal and mitochondrial proteins in PCS, particularly associated with respiratory dysfunction and reduced functional capacity. The results also highlight potential limitations of standard cognitive screening tools like the MoCA in detecting subtle deficits in PCS. The identified autoantibodies may serve as biomarkers for persistent post-COVID disability. Future research replicating present results on larger samples and specifically investigating a causal link between occurrence of the Auto-Abs and PCS is needed for shaping future immunomodulatory therapeutic strategies.
000281503 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281503 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281503 650_7 $$2Other$$aautoantibodies
000281503 650_7 $$2Other$$aautoimmunity
000281503 650_7 $$2Other$$abrainstem
000281503 650_7 $$2Other$$amitochondria
000281503 650_7 $$2Other$$apost COVID
000281503 650_7 $$2NLM Chemicals$$aAutoantibodies
000281503 650_7 $$2NLM Chemicals$$aImmunoglobulin G
000281503 650_7 $$2NLM Chemicals$$aMitochondrial Proteins
000281503 650_7 $$2NLM Chemicals$$aAutoantigens
000281503 650_7 $$2NLM Chemicals$$aBiomarkers
000281503 650_7 $$2NLM Chemicals$$aMembrane Proteins
000281503 650_7 $$2NLM Chemicals$$aNerve Tissue Proteins
000281503 650_7 $$2NLM Chemicals$$aAdaptor Proteins, Signal Transducing
000281503 650_2 $$2MeSH$$aHumans
000281503 650_2 $$2MeSH$$aAutoantibodies: blood
000281503 650_2 $$2MeSH$$aAutoantibodies: immunology
000281503 650_2 $$2MeSH$$aFemale
000281503 650_2 $$2MeSH$$aMale
000281503 650_2 $$2MeSH$$aMiddle Aged
000281503 650_2 $$2MeSH$$aCOVID-19: immunology
000281503 650_2 $$2MeSH$$aCOVID-19: complications
000281503 650_2 $$2MeSH$$aSARS-CoV-2: immunology
000281503 650_2 $$2MeSH$$aAged
000281503 650_2 $$2MeSH$$aImmunoglobulin G: blood
000281503 650_2 $$2MeSH$$aImmunoglobulin G: immunology
000281503 650_2 $$2MeSH$$aAdult
000281503 650_2 $$2MeSH$$aMitochondria: immunology
000281503 650_2 $$2MeSH$$aMitochondrial Proteins: immunology
000281503 650_2 $$2MeSH$$aAutoantigens: immunology
000281503 650_2 $$2MeSH$$aNeurons: immunology
000281503 650_2 $$2MeSH$$aBiomarkers: blood
000281503 650_2 $$2MeSH$$aPost-Acute COVID-19 Syndrome
000281503 650_2 $$2MeSH$$aMembrane Proteins: immunology
000281503 650_2 $$2MeSH$$aNerve Tissue Proteins: immunology
000281503 650_2 $$2MeSH$$aAdaptor Proteins, Signal Transducing: immunology
000281503 7001_ $$aSteinmetz, Anke$$b1
000281503 7001_ $$aStufano, Angela$$b2
000281503 7001_ $$aSchino, Valentina$$b3
000281503 7001_ $$aPlantone, Domenico$$b4
000281503 7001_ $$0P:(DE-2719)2812683$$aFlöel, Agnes$$b5$$udzne
000281503 7001_ $$aLucchese, Guglielmo$$b6
000281503 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2025.1642250$$gVol. 16, p. 1642250$$p1642250$$tFrontiers in immunology$$v16$$x1664-3224$$y2025
000281503 8564_ $$uhttps://pub.dzne.de/record/281503/files/DZNE-2025-01124.pdf$$yOpenAccess
000281503 8564_ $$uhttps://pub.dzne.de/record/281503/files/DZNE-2025-01124.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281503 909CO $$ooai:pub.dzne.de:281503$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000281503 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812683$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000281503 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281503 9141_ $$y2025
000281503 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000281503 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000281503 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281503 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2022$$d2024-12-28
000281503 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-12-29T15:23:07Z
000281503 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-12-29T15:23:07Z
000281503 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000281503 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000281503 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000281503 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281503 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-12-29T15:23:07Z
000281503 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000281503 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2022$$d2024-12-28
000281503 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000281503 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000281503 9201_ $$0I:(DE-2719)5000081$$kAG Flöel$$lDementia Prevention – Mechanisms and Clinical Implementation$$x0
000281503 980__ $$ajournal
000281503 980__ $$aVDB
000281503 980__ $$aUNRESTRICTED
000281503 980__ $$aI:(DE-2719)5000081
000281503 9801_ $$aFullTexts